Yuhan Corp. (000100)
Korea Stock Exchange · Korea · prices in KRW · close of 23 Oct 2026
Key indicators
| Last close | KRW 84,700.00 |
|---|---|
| 52-week range | 65,000.00 – 129,200.00 |
| Return, 1 month / 3 months | +14.3% / +18.6% |
| Return, 1 year / 3 years | −26.3% / +45.8% |
| Trend | Below its 200-day average |
| RSI (14) | 62 |
| Volatility (1 year) | 41.7% |
| Worst drawdown (1 year) | -46.6% |
| Average daily value traded | 21,884.16M KRW |
| Dividend yield | 0.7% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Yuhan Corporation is a South Korean pharmaceutical and consumer goods company based in Seoul. It develops and makes prescription medicines and over-the-counter drugs, including treatments for tuberculosis and other infectious diseases, along with remedies for erectile dysfunction and chronic conditions. The company also produces everyday household items such as toothpaste, soap and detergents. Its customers include hospitals, clinics, pharmacies and general consumers in Korea, and it works with international partners on some medicines.
Yuhan Corp. trades under the code 000100 on the Korea Stock Exchange in Korea, with its price quoted in South Korean won (KRW). Our dividend records, which start in 2019, show payments in 7 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Yuhan Corp. (000100) trades on the Korea Stock Exchange in Korea. It last closed at KRW 84,700.00 on 23 October 2026.
Its price-based Market X-Ray is 61 out of 100 (a fair price profile), ranking 290 of 934 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 26.3% and over the last three months it rose 18.6%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Korea Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 61 · Fair | Mixed trend against its averages. | |
| Above 200-day average | -4.1% | ||
| From 52-week high | -32.2% | ||
| Momentum | 61 · Fair | Typical recent returns for this exchange. | |
| 3-month return | 18.6% | ||
| 6-month return | -10.6% | ||
| 12-month return, skipping the last month | -35.5% | ||
| Stability (higher is calmer) | 56 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 41.7% | ||
| Worst drawdown, 1 year (smaller is calmer) | -46.6% | ||
| Liquidity | 88 · Strong | Trades actively. | |
| Average daily value traded | 21,884.16M KRW | ||
| Zero-volume days | 0.0% | ||
| Income | 30 · Weak | Dividend is small or irregular. | |
| Dividend yield | 0.7% | ||
| Years with dividends | 5 |
Strengths
- Liquidity: Trades actively.
Weak spots
- Income: Dividend is small or irregular.
Returns
| 1 week | +5.3% |
|---|---|
| 1 month | +14.3% |
| 3 months | +18.6% |
| 6 months | −10.6% |
| 1 year | −26.3% |
| 3 years | +45.8% |
| 5 years | +63.4% |
Signals
| 50-day / 200-day average | 79,664.00 / 88,348.36 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | Yes |
| Average daily range (ATR) | 3,320.84 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 26 Feb 2026 | KRW 600.0000 |
| 27 Dec 2024 | KRW 500.0000 |
| 27 Dec 2023 | KRW 472.5000 |
| 28 Dec 2022 | KRW 420.0000 |
| 29 Dec 2021 | KRW 420.0000 |
| 29 Dec 2020 | KRW 400.0000 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Korea Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.